US 12,173,282 B2
Antibodies that bind CD3 epsilon
Aaron Sato, Burlingame, CA (US); Pankaj Garg, Burlingame, CA (US); Qiang Liu, Palo Alto, CA (US); and Tom Yuan, South San Francisco, CA (US)
Assigned to Twist Bioscience, Inc., South San Franscisco, CA (US)
Filed by Twist Bioscience Corporation, South San Francisco, CA (US)
Filed on Sep. 23, 2020, as Appl. No. 17/030,232.
Claims priority of provisional application 62/904,620, filed on Sep. 23, 2019.
Claims priority of provisional application 62/935,603, filed on Nov. 14, 2019.
Claims priority of provisional application 62/945,761, filed on Dec. 9, 2019.
Prior Publication US 2021/0102195 A1, Apr. 8, 2021
Int. Cl. C12N 15/10 (2006.01); C07K 16/28 (2006.01)
CPC C12N 15/1068 (2013.01) [C07K 16/2803 (2013.01); C07K 16/2869 (2013.01); C07K 16/2896 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 9 Claims
 
1. An antibody or antibody fragment that binds to CD3 epsilon, wherein the antibody or antibody fragment comprises a CDRH1, CDRH2, and CDRH3 on a variable region of a heavy chain (VH) and a CDRL1, CDRL2, and CDRL3 on a variable region of a light chain (VL); wherein the CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences of SEQ ID NOs: 118, 121, 124, 129, 132, and 135, respectively; or SEQ ID NOs: 119, 122, 125, 130, 133, and 136, respectively; or SEQ ID NOs: 120, 123, 126, 131, 134, and 137, respectively.